GigaGen Awarded U.S. BARDA Contract to Develop Recombinant Polyclonal Antibody Therapies for Botulinum Neurotoxins and an Additional Biothreat

Oct 03, 2024•over 1 year ago

Contract Type

contract

San FranciscoHealthcare

Description

GigaGen Inc., a subsidiary of Grifols, has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA) to develop a recombinant polyclonal antibody therapy for botulinum neurotoxins (BoNT) and a second biothreat.

Company Information

Company

GigaGen, Inc.

Location

407 CABOT ROAD

San Francisco, California, United States

About

Billions of immune cells in your bloodstream fight disease on a daily basis. GigaGen turns these cells into life-saving medical therapies.

Related People

Agreement Insights

Based on industry data
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months